---
schema_version: "secwatch.filing_event.v1"
accession: "0001650664-26-000093"
form_type: "8-K"
ticker: "EDIT"
cik: "0001650664"
company_name: "Editas Medicine, Inc."
filed_at: "2026-10-08T11:04:33+00:00"
generated_at: "2026-10-12T15:39:19.320972+00:00"
event_type: "regulatory"
sentiment: "positive"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Editas receives Australian approval to initiate Phase 1/2 Strive trial of EDIT-401 in HeFH

## Summary
- Australia's TGA and HREC cleared the Phase 1/2 Strive trial of EDIT-401; a submission is also under review in New Zealand, with five trial sites selected across both countries.
- Strive is two-part: Part 1 single ascending dose, open-label; Part 2 single-dose, randomized, placebo-controlled. Initial safety/tolerability data expected Q1 2027. Topline later in 2027.
- Preclinical data showed ~90% or greater mean reduction in LDL-C, Lp(a) and ApoB in non-human primates; ~90% LDL-C reduction was maintained over 10 months.
- Editas will present EDIT-401 durability data at AHA Scientific Sessions on Nov 8, 2026, in Chicago; CMO Dan Ory, M.D. is the presenter.
- Editas remains on track to begin patient dosing in 2026 and plans to complete Part 1 enrollment with topline safety and efficacy results later in 2027.

## SEC filing metadata
- accession: 0001650664-26-000093
- form_type: 8-K
- ticker: EDIT
- cik: 0001650664
- company_name: Editas Medicine, Inc.
- filed_at: 2026-10-08T11:04:33+00:00
- event_type: regulatory
- sentiment: positive
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 7.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1650664/000165066426000093/0001650664-26-000093-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1650664/000165066426000093/edit-20261008.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001650664-26-000093
- JSON: https://secwatch.observer/filing/0001650664-26-000093.json
- Plain text: https://secwatch.observer/filing/0001650664-26-000093.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.